MindMed to Present at the Jefferies London Healthcare Conference
On November 12, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that its CEO, Robert Barrow, will speak at the Jefferies 2021 London Healthcare Conference from November 16-19.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On November 12, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that its CEO, Robert Barrow, will speak at the Jefferies 2021 London Healthcare Conference from November 16-19. The management team will be available for both in-person and virtual one-on-one meetings. A webcast of Barrow's presentation will be available on-demand starting November 17 at 9:20 AM GMT. MindMed is focused on developing psychedelic-inspired therapies for mental illness.
Details
News Market Reaction – MNMD
The recorded move for MNMD in the trading session of this news was +6.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.
A video webcast of the presentation will be available for viewing on-demand beginning on Wednesday, November 17 at 9:20 AM GMT for those registered for the event. The webcast will also be accessible in the "Investors" section of MindMed's website. MindMed will maintain an archived replay of the webcast on its website for 30 days after the conference.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Media Contact: mindmed@150bond.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-present-at-the-jefferies-london-healthcare-conference-301422852.html
SOURCE Mind Medicine (MindMed) Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.